Literature DB >> 7424885

"Alternative" controls in a case-control study of endometrial cancer and exogenous estrogen.

B S Hulka, R C Grimson, B G Greenberg, D G Kaufman, W C Fowler, C J Hogue, G S Berger, C C Pulliam.   

Abstract

To address the issue of detection bias among endometrial cancer cases and controls, women admitted to the North Carolina Memorial Hospital for dilatation and curettage (D&C) during 1970-1976 were selected as one of three control groups in a study of endometrial cancer and exogenous estrogen. Study subjects included 256 cases, 316 D&C controls, 224 gynecology controls and 321 community controls. The D&C controls had a higher frequency of estrogen use than either of the other control groups or the cases. These differences existed for both blacks and whites. When white cases were compared to either gynecology or community controls, relative risks were increased for long duration estrogen use and for recent use prior to diagnosis. With D&C controls, relative risks were not significantly different from unity irrespective of duration or recency of estrogen use. Exclusion of hyperplasias from the D&C controls had no substantive effect of these results. Bleeding was a presenting complaint for 92% of cases, 82% of D&C controls and 22% of gynecology controls. Both among cases and gynecology controls, there was no statistically significant association between bleeding and estrogen use, whereas this association was evident among D&C controls, and specifically among those who did not have pathologic evidence of endometrial hyperplasia. These data support the presence of detection bias among D&C controls but they do not provide evidence of this bias among endometrial cancer cases.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7424885     DOI: 10.1093/oxfordjournals.aje.a113003

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  7 in total

1.  Estrogens and endometrial cancer: some answers and some further questions.

Authors:  J M Elwood
Journal:  Can Med Assoc J       Date:  1981-05-01       Impact factor: 8.262

2.  Comparison of megestrol acetate and clomiphene citrate as supplemental medication in postmenopausal oestrogen replacement therapy.

Authors:  A Kauppila; S Kivinen; P Leinonen; R Tuimala; R Vihko; P Ylöstalo
Journal:  Arch Gynecol       Date:  1983

3.  Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis.

Authors:  Megan A Clarke; Beverly J Long; Arena Del Mar Morillo; Marc Arbyn; Jamie N Bakkum-Gamez; Nicolas Wentzensen
Journal:  JAMA Intern Med       Date:  2018-09-01       Impact factor: 21.873

4.  Endometrial cancer risk after discontinuing use of unopposed conjugated estrogens (California, United States).

Authors:  W D Finkle; S Greenland; O S Miettinen; H K Ziel
Journal:  Cancer Causes Control       Date:  1995-03       Impact factor: 2.506

5.  Risk factors of female cancers in Ragusa population (Sicily)--1. Endometrium and cervix uteri cancers.

Authors:  R Cusimano; G Dardanoni; L Dardanoni; M La Rosa; G Pavone; R Tumino; L Gafà
Journal:  Eur J Epidemiol       Date:  1989-09       Impact factor: 8.082

6.  Asthma and risk of glioma: a population-based case-control study.

Authors:  Harsheen Kaur; Daniel H Lachance; Conor S Ryan; Youn Ho Sheen; Hee Yun Seol; Chung-Il Wi; Sunghwan Sohn; Katherine S King; Euijung Ryu; Young Juhn
Journal:  BMJ Open       Date:  2019-06-17       Impact factor: 2.692

7.  Comparative study of control selection in a national population-based case-control study: Estimating risk of smoking on cancer deaths in Chinese men.

Authors:  Jingmei Jiang; Boqi Liu; Philip C Nasca; Wei Han; Xiaonong Zou; Xianjia Zeng; Xiaobing Tian; Yanping Wu; Ping Zhao; Junyao Li
Journal:  Int J Med Sci       Date:  2009-10-28       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.